Drugs / NNC0491-6075
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05979428 | Aug 2023 → Mar 2025 | hyperlipidemia | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0491-6075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05979428 ↗ |
| Route | Subcutaneous | “NNC0491-6075 will be administered as a subcutaneous injection” NCT05979428 ↗ |